Heterogeneity in families with ATTRV30M amyloidosis: a historical and longitudinal Portuguese case study impact for genetic counselling

References

• Andrade C. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain. 1952;75(3):408–427. doi:10.1093/brain/75.3.408.
   PubMed Web of Science ®Google Scholar
• Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the international society of amyloidosis (ISA) nomenclature committee. Amyloid. 2020;27(4):217–222. doi:10.1080/13506129.2020.1835263.
   PubMed Web of Science ®Google Scholar
• Coelho MTPM. Disease modifying therapies for ATTR amyloidosis: Clinical development of new drugs and impact on the natural history of the disease [Ph.D. thesis]. School of Medicine and Biomedical Sciences - University of Porto, Porto; 2019.
   Google Scholar
• Dispenzieri A, Coelho T, Conceição I, et al. Clinical and genetic profile of patients enrolled in the transthyretin amyloidosis outcomes survey (THAOS): 14-year update. Orphanet J Rare Dis. 2022;17(1):236. doi:10.1186/s13023-022-02359-w.
   PubMed Web of Science ®Google Scholar
• Adams D, Ando Y, Beirão JM, et al. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. 2021;268(6):2109–2122. doi:10.1007/s00415-019-09688-0.
   PubMed Web of Science ®Google Scholar
• Rapezzi C, Quarta CC, Obici L, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520–528. doi:10.1093/eurheartj/ehs123.
   PubMed Web of Science ®Google Scholar
• Alves-Ferreira M, Azevedo A, Coelho T, et al. Beyond Val30Met transthyretin (TTR): variants associated with age-at-onset in hereditary ATTRv amyloidosis. Amyloid. 2021;28(2):100–106. doi:10.1080/13506129.2020.1857236.
   PubMed Web of Science ®Google Scholar
• Alarcon F, Planté-Bordeneuve V, Nuel G. Study of the parent-of-origin effect in monogenic diseases with variable age of onset. Application on ATTRv. PLOS One. 2023;18(8):e0288958. doi:10.1371/journal.pone.0288958.
   PubMed Web of Science ®Google Scholar
• Gorram F, Olsson M, Alarcon F, et al. New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden. Amyloid. 2021;28(2):84–90. doi:10.1080/13506129.2020.1841623.
   PubMed Web of Science ®Google Scholar
• Planté-Bordeneuve V, Gorram F, Olsson M, et al. A multicentric study of the disease risks and first manifestations in hereditary transthyretin amyloidosis (ATTRv): insights for an earlier diagnosis. Amyloid. 2023;30(3):313–320. doi:10.1080/13506129.2023.2178891.
   PubMed Web of Science ®Google Scholar
• Waddington-Cruz M, Schmidt H, Botteman MF, et al. Epidemiological and clinical characteristics of symptomatic hereditary transthyretin amyloid polyneuropathy: a global case series. Orphanet J Rare Dis. 2019;14(1):34. doi:10.1186/s13023-019-1000-1.
   PubMed Web of Science ®Google Scholar
• Inês M, Coelho T, Conceição I, et al. Epidemiology of transthyretin familial amyloid polyneuropathy in Portugal: a nationwide study. Neuroendocrinology. 2018;51(3–4):177–182. doi:10.1159/000490553.
   Google Scholar
• Tetushkin EY. Genetic aspects of genealogy. Russ J Genet. 2011;47(11):1288–1306., doi:10.1134/S1022795411110160.
   Web of Science ®Google Scholar
• Ando Y, Waddington-Cruz M, Sekijima Y, et al. Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal. Orphanet J Rare Dis. 2023;18(1):323. doi:10.1186/s13023-023-02910-3.
   PubMed Web of Science ®Google Scholar
• Conceição I, Damy T, Romero M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations*. Amyloid. 2019;26(1):3–9. doi:10.1080/13506129.2018.1556156.
   PubMed Web of Science ®Google Scholar
• Lemos C, Coelho T, Alves-Ferreira M, et al. Overcoming artefact: anticipation in 284 portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M. J Neurol Neurosurg Psychiatry. 2014;85(3):326–330., https://www.ncbi.nlm.nih.gov/pubmed/24046394 doi:10.1136/jnnp-2013-305383.
   PubMed Web of Science ®Google Scholar
• Mendes MF. Como Nascem e Morrem os Portugueses—nascimentos, natalidade, fecundidade, óbitos, mortalidade, causas de morte. Fundação Francisco Manuel dos Santos; 2020. https://www.pordata.pt/publicacoes/livros/como+nascem+e+morrem+os+portugueses-180.
   Google Scholar
• Moreira CL, Rocha A, Santos J, et al. The ever-growing understanding of transthyretin amyloidosis nephropathy. Amyloid. 2017;24(sup1):117–118. doi: 10.1080/13506129.2017.1293645.
   PubMed Web of Science ®Google Scholar
• Lobato L, Rocha A. Transthyretin amyloidosis and the kidney. Clin J Am Soc Nephrol. 2012;7(8):1337–1346. doi:10.2215/CJN.08720811.
   Google Scholar
• Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Failure. 2019; 6(6):1128–1139. doi: 10.1002/ehf2.12518.
   PubMed Web of Science ®Google Scholar
• Beauvais D, Labeyrie C, Cauquil C, et al. Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers. J Neurol Neurosurg Psychiatry. 2023;:jnnp-2023-332180. Advance online publication. doi: 10.1136/jnnp-2023-332180.
   Web of Science ®Google Scholar